Effect of Nutritional Products in Subjects With Type 2 Diabetes

Diabetes Clinical Trial

Official title:

Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02923960
• Other study ID #: BL33
• Status: Completed
• Phase: N/A
• First received: October 3, 2016
• Last updated: April 14, 2017
• Start date: October 2016
• Est. completion date: January 2017

Study information

• Verified date: April 2017
• Source: Abbott Nutrition
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double blinded, multi treatment, crossover study intended to compare the glycemic and insulinemic response after consuming liquid nutritional products in people with type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subject has type 2 diabetes

• Subject is a male or a nonpregnant, nonlactating female, at least 6 weeks postpartum prior to screening visit

• Subject's BMI is > 18.5 kg/m2 and < 35 kg/m2

• If on a chronic medication such as antihypertensive, lipid lowering, thyroid medication or hormone therapy, subject has been on constant dosage for at least two months prior to screening visit

• Subject states willingness to follow protocol as described, including consumption of study product per protocol and completing any required study forms

• Participant must refrain from taking medications/dietary supplements/herbals or substances that could modulate glucose metabolism (other than oral hypoglycemic medications), or considered anabolic, or reduce weight (fat mass)

Exclusion Criteria:

• Subject is currently diagnosed with, or has a history of severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures

• Subject is known to be allergic or intolerant to any ingredient found in the study products

• Subject is participating in another study that has not been approved as a concomitant study

• Subject uses exogenous insulin for glucose control, or subject states that they have been diagnosed as having Type 1 diabetes

• Subject states they have a history of diabetic ketoacidosis

• Subject is currently on a low carbohydrate or very low carbohydrate diet

• Subject states that he/she has a current infection; has had inpatient surgery, or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior to screening visit

• Subject states that he/she has an active malignancy

• Subject states that he/she has had a significant cardiovascular event = six months prior to screening visit; or stated history of congestive heart failure

• Subject states that he/she has end stage organ failure or is status post organ transplant

• Subject is diagnosed with chronic kidney disease, or a history of kidney issues

• Subject states they have impaired liver function, or have a history of liver disease

• Subject has an obstruction of the gastrointestinal tract precluding ingestion of the study product, inflammatory bowel disease, short bowel syndrome or other severe forms of gastrointestinal disease such as gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, or ischemic colitis, or any other related condition that may cause unnecessary subject discomfort

• Subject states they have a chronic, contagious, infectious disease

• Subject has taken/is currently taking any herbals, dietary supplements, or medications during the past four weeks prior to screening visit that are designed to affect blood glucose.

• Subject states that he/she has clotting or bleeding disorders

• If selected for continuous blood glucose monitoring, subject has skin lesions, hyperhidrosis, eczema, psoriasis, scarring, redness, infection or edema at the flash constant glucose monitoring application site(s) that could interfere with device placement or the accuracy of interstitial glucose measurements.

• If selected for continuous blood glucose monitoring, subject has an X-ray, MRI or CT appointment scheduled during the period of study participation, or another procedure that would require removal of the flash constant glucose monitoring sensor.

• Subjects on sulfonylureas, meglitinides, and a-glucosidase inhibitors, insulin, or subject on more than two oral hypoglycemic medications excluding aforementioned.

• Subjects on oral hypoglycemic medications that has changed in last 2 months.

• Subject's HbA1c, per point of care device is > 8%

Related Conditions & MeSH terms

• Diabetes
• Diabetes Mellitus

Intervention

Other:
• Standard ONS
One serving (237 ml) standard oral nutritional beverage
• Diabetes specific ONS 1
One serving (237 ml) diabetes oral nutritional beverage
• Diabetes specific ONS 2
One serving (296 ml) diabetes oral nutritional beverage

Locations

Country	Name	City	State
United States	Great Lakes Clinical Trials	Chicago	Illinois
United States	Radiant Research, Inc.	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Nutrition

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma Glucose Concentration		0 to 240 minutes
Secondary	Serum Insulin Concentration		0 to 240 minutes